Although anti-TNFα unveils a new treatment for IBD, up to 30% of patients show primary nonresponse (PNR), and another 40% lose response over time, i.e., secondary loss of response (SLR) and need to switch therapy (Papamichael et al., 2015). This evidence concerns the gene TNF and inflammatory bowel disease.